749021
Last Update Posted: 2012-10-05
Recruiting has ended
All Genders accepted | 50 Years + |
40 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
This is a multicenter, randomized, open-label study. 40 patients will be followed for a period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg of intravitreal ranibizumab injection.
Eligibility
Relevant conditions:
Retinal Pigment Epithelial Detachment
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov